PTPN 2 phosphatase deletion in T cells promotes anti‐tumour immunity and CAR T‐cell efficacy in solid tumours-Reference-Cited by-同舟云学术

PTPN 2 phosphatase deletion in T cells promotes anti‐tumour immunity and CAR T‐cell efficacy in solid tumours

Published:2019-12-05 Issue:2 Volume:39 Page:
ISSN:0261-4189
Container-title:The EMBO Journal
language:en
Short-container-title:EMBO J

Author:

Wiede Florian¹²³^ORCID,Lu Kun‐Hui³,Du Xin³⁴,Liang Shuwei¹²³,Hochheiser Katharina³⁵⁶,Dodd Garron T¹²,Goh Pei K¹²³,Kearney Conor³,Meyran Deborah³,Beavis Paul A³⁴,Henderson Melissa A³,Park Simone L⁵⁶,Waithman Jason⁷,Zhang Sheng⁸,Zhang Zhong‐Yin⁸,Oliaro Jane³⁴,Gebhardt Thomas⁵⁶,Darcy Phillip K³⁴,Tiganis Tony¹²³^ORCID

Affiliation:

1. Monash Biomedicine Discovery Institute Monash University Clayton Vic. Australia

2. Department of Biochemistry and Molecular Biology Monash University Clayton Vic. Australia

3. Peter MacCallum Cancer Centre Melbourne Vic. Australia

4. Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne Vic. Australia

5. Department of Microbiology and Immunology The University of Melbourne Melbourne Vic. Australia

6. Peter Doherty Institute for Infection and Immunity Melbourne Vic. Australia

7. Telethon Kids Institute University of Western Australia Perth WA Australia

8. Department of Medicinal Chemistry and Molecular Pharmacology Institute for Drug Discovery Purdue University West Lafayette IN USA

Funder

National Health and Medical Research Council

National Institutes of Health

Cancer Council Victoria

Publisher

EMBO

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/embj.2019103637

Reference83 articles.

1. Treatment of HER2-positive breast cancer: current status and future perspectives

2. STAT1‐associated intratumoural T H 1 immunity predicts chemotherapy resistance in high‐grade serous ovarian cancer

3. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

4. Toxicity and management in CAR T-cell therapy

5. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy;European Journal of Medicinal Chemistry;2024-11

2. Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

3. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors;Seminars in Immunopathology;2024-07-25

4. From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond;Pharmaceutics;2024-07-01

5. Self-reinforcing nano-spearhead drives the efficacy of CAR-T cells against progressive triple negative breast cancer;Materials Today;2024-07